Roche Holding AG Deal History & Licensing Activity
Roche Holding AG is a life sciences. Over the past three years, Roche Holding AG has been involved in 15 licensing and acquisition transactions, with a primary focus on Small Molecules (9 deals).
Deals (12mo)
11
Active Trials
0
Top Modality
Small Molecules
Focus Area
Oncology
Roche Holding AG Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Roche Holding AG in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| HM17321 | Roche | Small Molecules | Phase 1 | license | Aug 24, 2026 |
| Zenapax (asthma/respiratory disorders) | Roche | Antibodies | Unknown | co development | Jul 12, 2026 |
| PathAI digital pathology platform | PathAI | Other | Unknown | acquisition | Jul 10, 2026 |
| Undisclosed | Roche | Small Molecules | Discovery | collaboration | Jul 6, 2026 |
| YL201 | Roche | ADC | Preclinical | license | Jan 8, 2026 |
| Undisclosed | Roche | Small Molecules | Phase 1 | license | Jan 7, 2026 |
| Undisclosed | Roche | Other | Discovery | collaboration | Dec 17, 2025 |
| Undisclosed | Roche | Antibodies | Discovery | collaboration | Nov 3, 2025 |
| pegozafermin | Roche | Peptides | Phase 2 | acquisition | Oct 30, 2025 |
| QX031N | Roche | Bispecific Antibodies | Phase 1 | license | Oct 30, 2025 |
Showing 10 of 11 recent transactions. Upgrade to Pro for full deal history with financials.
Roche Holding AG Pipeline Focus
Therapeutic areas and modalities where Roche Holding AG is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Roche Holding AG's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Roche Holding AG Licensing & Deal Activity
Roche Holding AG is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 15 deals over the past three years, Roche Holding AG ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Roche Holding AG include Oncology (11 deals and trials), Metabolic (6 deals and trials), Codev Deals (3 deals and trials), and Mega Deals (2 deals and trials). In terms of modality, Roche Holding AG has shown particular interest in small molecules, other, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Roche Holding AG and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Roche Holding AG's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.